Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 16, 2005

View Archived Issues

Update on TGN-255 in the prevention of thrombosis

Add-on topiramate prevents body weight gain in schizophrenics treated with antipsychotics

Novel delivery of contortrostatin provides enhanced potential for clinical development

Halofuginone modulates T-cell functional activity

Cell death pathways investigated in TH-9402-mediated cytotoxicity

BMS-593214: a novel inhibitor of FVIIa

Natriuretic peptides may help predict outcome of patients with nonischemic CHF

Urocortin 2 shows promise in the treatment of congestive heart failure

Clinical data confirm the efficacy of solifenacin in overactive bladder

AL-208 set to enter phase I trials

Enrollment completed in U.S. phase I study of cetilistat for obesity

Agenix contracts Diosynth for manufacturing of ThromboView

BioSante licenses contraceptive technology from Wake Forest University

YM BioSciences licenses oncology compounds from U. of Saskatchewan

Phase II comparative study of R-112 for allergic rhinitis opens enrollment

AmpliMed licenses FB-642 and other compounds from UTR

CytoGenix forms research collaboration with Imperial College London

Encore awarded SBIR grant for work in neuroinflammation

Cenix delivers therapeutic targets to Bayer

Phase II trial begins for OGX-011 for NSCLC

Velcura and Nippon Chemiphar collaborate on osteoporosis drugs

NS-2330 results do not warrant phase III studies in Alzheimer's, Parkinson's

Pfizer submits Sutent NDA

Bioequivalence studies continue for fixed-dose Truvada/Sustiva product

Recent patents describe new antiinfective agents

New agents for treating obesity disclosed by Procter & Gamble

Novel therapeutics for fibroproliferative diseases reported by Scios

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...